Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent Hodgkin lymphoma

Alagöz, Engin; İnce, Semra; Okuyucu, Kürşat; Ayan, Aslı; Şan, Hüseyin; BALKAN, Elif; Karadurmuş, Nuri

doi:10.21037/tcr.2016.06.02

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Uptake by the T cells might affect the evaluation of immunotherapy. To date, there is only one report except our case, which showed the usefulness of FDG-PET/CT to evaluate the efficacy of nivolumab in a patient with indolent Hodgkin lymphoma [ 21 ]. Although we usually evaluate the anatomic tumor response with RECIST [ 16 ] or immune-related Response Criteria (irRC) [ 22 ] after cancer treatment, Wall et al [ 23 ] proposed PET Response Criteria in Solid Tumors version 1.0 (PERCIST) to assess the treatment response instead of RECIST.…”

Section: Case Presentationmentioning

confidence: 99%

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer

et al. 2016

View full text Add to dashboard Cite

BackgroundNivolumab, an immune checkpoint inhibitor, is recently clinically applied to non-small cell lung cancer (NSCLC) treatment, and this causes T cell activation and T cell infiltration to tumor tissue through the blockade of the interaction between programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1). 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) sometimes shows false positive because of the recruitment of neutrophils, lymphocytes, and macrophages. To date, there is only one report except our case, which described the correlation between FDG-PET and nivolumab.Case presentationWe report on a 75-year-old man on nivolumab treatment for metastatic non-small cell lung cancer. He had undergone right lower lobectomy for lung adenocarcinoma in the right S8 segment 10 months prior to recurrence. Pathological findings revealed invasive adenocarcinoma, pT1bN2M0 stage IIIA. Epidermal growth factor receptor (EGFR) mutation was positive for de novo T790M and anaplastic lymphoma kinase (ALK) rearrangement was negative. Immunohistochemistry was negative for PD-L1. He underwent chemotherapy with a combination of cisplatin and pemetrexed for four cycles but developed progressive disease involving the right hemithorax, multiple lymph nodes, and multiple osseous sites. Nivolumab was instituted as a second-line chemotherapy. After six courses of this immunotherapy, FDG-PET scan showed decreased FDG uptake in each recurrent lesion despite T lymphocyte activation by nivolumab. Serum carcinoembryonic antigen (CEA) level was also remarkably decreased.ConclusionsNivolumab’s effect on recurrent NSCLC may be monitored by PET; larger studies are needed.

show abstract

Section: Case Presentationmentioning

confidence: 99%

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Two forms of intravascular delivery of radiation therapy are well established in the clinical realm: peptide receptor radionuclide therapy (PRRT) and selective internal radiation therapy (SIRT). PRRT uses radiopeptides targeted against cancer-specific receptors to deliver radiation therapy, while SIRT uses selective intra-arterial (IA) infusion of radioembolics via tumor vasculature to irradiate tumors and stunt blood supply to tumors (Bodei et al, 2011;Arslan et al, 2021). Both methods rely on beta (β-)-emitting isotopes, namely for PRRT and Yttrium-90 (Y-90) for SIRT (Kauffman et al, 2023).…”

Section: Introductionmentioning

confidence: 99%

Effective therapy with Bismuth-212 labeled macroaggregated albumin in orthotopic mouse breast tumor models

Kauffman

Singh

Morrison³

et al. 2023

Front. Chem.

View full text Add to dashboard Cite

Intravascularly administered radiation therapy using beta (β-)-emitting radioisotopes has relied on either intravenously injected radiolabeled peptides that target cancer or radiolabeled microspheres that are trapped in the tumor following intra-arterial delivery. More recently, targeted intravenous radiopeptide therapies have explored the use of alpha (α)-particle emitting radioisotopes, but microspheres radiolabeled with α-particle emitters have not yet been studied. Here, FDA-approved macroaggregated albumin (MAA) particles were radiolabeled with Bismuth-212 (Bi-212-MAA) and evaluated using clonogenic and survival assays in vitro and using immune-competent mouse models of breast cancer. The in vivo biodistribution of Bi-212-MAA was investigated in Balb/c and C57BL/6 mice with 4T1 and EO771 orthotopic breast tumors, respectively. The same orthotopic breast cancer models were used to evaluate the treatment efficacy of Bi-212-MAA. Our results showed that macroaggregated albumin can be stably radiolabeled with Bi-212 and that Bi-212-MAA can deliver significant radiation therapy to reduce the growth and clonogenic potential of 4T1 and EO771 cells in vitro. Additionally, Bi-212-MAA treatment upregulated γH2AX and cleaved Caspase-3 expression in 4T1 cells. Biodistribution analyses showed 87–93% of the Bi-212-MAA remained in 4T1 and EO771 tumors 2 and 4 h after injection. Following single-tumor treatments with Bi-212-MAA there was a significant reduction in the growth of both 4T1 and EO771 breast tumors over the 18-day monitoring period. Overall, these findings showed that Bi-212-MAA was stably radiolabeled and inhibited breast cancer growth. Bi-212-MAA is an exciting platform to study α-particle therapy and will be easily translatable to larger animal models and human clinical trials.

show abstract

The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring

Yao

Zhou

Zhang

et al. 2022

European Journal of Radiology

View full text Add to dashboard Cite

Complete remission on 18-fluorodeoxyglucose positron emission tomography/computed tomography after nivolumab treatment in a patient with indolent Hodgkin lymphoma

Cited by 3 publications

References 0 publications

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer

FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer

Effective therapy with Bismuth-212 labeled macroaggregated albumin in orthotopic mouse breast tumor models

The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer: Precision medicine and visual monitoring

Contact Info

Product

Resources

About